It’s no longer Trudeau: Canada’s PM resigns
The Intelligence from The Economist
Challenges and Optimism in AI-Driven Drug Development
This chapter explores the intricate challenges of drug development and the role of AI technologies in this process. It offers a cautiously optimistic perspective on AI's potential to improve drug approval rates, despite recent hurdles faced by AI-driven startups in clinical trials.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
